300813.SHE Zhejiang Tailin Bioengineering Co Ltd
- Market cap
- CNY 2.20B
- P/E
- 90.9x
- P/B
- 2.83x
- ROE
- 4.6%
- Dividend yield
- 1.10%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 300813.SHE undervalued?
Graham numberThe Graham number of Zhejiang Tailin Bioengineering Co Ltd cannot be estimated reliably (the estimate is too far from the market price).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Zhejiang Tailin Bioengineering Co Ltd fundamental analysis
No fundamental analysis for Zhejiang Tailin Bioengineering Co Ltd yet.
Zhejiang Tailin Bioengineering Co Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Zhejiang Tailin Bioengineering Co Ltd
Zhejiang Tailin BioEngineering Co.,Ltd engages in the research and development, production, and sale of microbial detection, contamination control, process analysis, and inhibition protection in the life sciences field in China and internationally. The company primarily offers aseptic production and contamination control equipment, microbial testing products, and organic matter analysis technology products. It also provides pharma processing, such as pharma isolators, high-p…
Full company profileZhejiang Tailin Bioengineering Co Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Zhejiang Tailin Bioengineering Co Ltd annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 112M | 142M | 159M | 181M | 200M | 283M | 374M | 270M | 349M | 334M | 340M |
| Gross Profit | 64.8M | 84.1M | 93.6M | 102M | 123M | 171M | 194M | 128M | 151M | 140M | 169M |
| Operating Income | 26.9M | 46.9M | 53.6M | 38.3M | 51.9M | 69.8M | 79.6M | 21.8M | 12.4M | 845K | 35.7M |
| EBITDA | 35.7M | 54.4M | 56.5M | 46.2M | 60.1M | 76.4M | 89.9M | 33.8M | 44.2M | 21.4M | 35.7M |
| Net Income | 29.0M | 45.0M | 48.2M | 34.4M | 48.4M | 63.5M | 79.7M | 19.7M | 13.1M | 16.5M | 37.4M |
| EPS | 0.36 | 0.56 | 0.60 | 0.42 | 0.46 | 0.58 | 0.71 | 0.17 | 0.12 | 0.14 | 0.31 |
| Balance Sheet | |||||||||||
| Total Assets | 156M | 194M | 255M | 267M | 540M | 656M | 923M | 974M | 960M | 959M | 962M |
| Total Liabilities | 39.7M | 47.1M | 60.4M | 37.8M | 95.7M | 158M | 275M | 323M | 139M | 155M | 156M |
| Shareholders' Equity | 116M | 146M | 195M | 229M | 444M | 497M | 647M | 649M | 820M | 804M | 806M |
| Cash & Short-term Investments | 66.0M | 67.0M | 44.4M | 51.9M | 322M | 323M | 577M | 397M | 265M | 333M | 163M |
| Total Debt | 137K | 19.5M | 2.28M | - | 3.75M | 12.9M | 145M | 158M | 3.67M | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 31.6M | 23.0M | 37.3M | 29.0M | 106M | 36.0M | 89.4M | 1.93M | 24.7M | 57.1M | - |
| Capital Expenditure | 14.2M | 26.5M | 42.3M | 22.4M | 7.07M | 25.9M | 29.1M | 176M | 18.5M | 46.9M | 54.8M |
| Free Cash Flow | 17.3M | -3.50M | -4.97M | 6.67M | 99.2M | 10.1M | 60.2M | -174M | 6.12M | 10.2M | 6.56M |
| Ratios | |||||||||||
| ROE | 24.9% | 30.7% | 24.8% | 15.0% | 10.9% | 12.8% | 12.3% | 3.0% | 1.6% | 2.0% | 4.6% |
| ROA | 18.6% | 23.2% | 18.9% | 12.9% | 9.0% | 9.7% | 8.6% | 2.0% | 1.4% | 1.7% | 3.9% |
| Net Profit Margin | 26.0% | 31.7% | 30.3% | 19.0% | 24.2% | 22.4% | 21.3% | 7.3% | 3.7% | 4.9% | 11.0% |
| Debt to Equity | 0.00x | 0.13x | 0.01x | - | 0.01x | 0.03x | 0.22x | 0.24x | 0.00x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Zhejiang Tailin Bioengineering Co Ltd dividends
- Dividend yield
- 1.10%
- Forward dividend
- 0.13 CNY
- Payout ratio
- 147.0%
- Ex-dividend date
- Sep 22, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 24.2M | 0.20 | 147.0% |
| 2024 | CNY 11.0M | 0.10 | 84.2% |
| 2023 | CNY 27.2M | 0.23 | 138.1% |
| 2022 | CNY 17.8M | 0.16 | 22.4% |
| 2021 | CNY 9.77M | 0.09 | 15.4% |
| 2020 | CNY 31.2M | 0.29 | 64.4% |
| 2019 | CNY 31.2M | 0.38 | 90.6% |
| 2018 | CNY 44.3K | 0.00 | 0.1% |
| 2017 | CNY 15.3M | 0.19 | 34.0% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1.3:1 on May 11, 2023.
Who owns Zhejiang Tailin Bioengineering Co Ltd
- Insiders 62.58%
- Institutions 1.20%
- Public & others 36.22%
- Shares outstanding 121M
- Free float 45.6M
Zhejiang Tailin Bioengineering Co Ltd company profile
- Company name
- Zhejiang Tailin Bioengineering Co Ltd
- Ticker
- 300813.SHE
- ISIN
- CNE100003S89
- Exchange
- Shenzhen Stock Exchange
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 790
- Fiscal year end
- December
- Address
- No. 2930, South Ring Road, Hangzhou, China, 310052
- Phone
- 86 571 8658 9087
- Website
- tailingood.com
About Zhejiang Tailin Bioengineering Co Ltd
Zhejiang Tailin BioEngineering Co.,Ltd engages in the research and development, production, and sale of microbial detection, contamination control, process analysis, and inhibition protection in the life sciences field in China and internationally. The company primarily offers aseptic production and contamination control equipment, microbial testing products, and organic matter analysis technology products. It also provides pharma processing, such as pharma isolators, high-precision filling and dispensing, sterile transfer; cell and gene therapy; radiopharma; laboratory animal; leak test systems; biodecontamination, including VH2O2 sterilization system and dry fogging system; sterilization monitoring and validation; microbiological testing, comprising sterility and microbial limit test system and pretreatment instruments; and water quality, consisting of microbial monitoring and aquatic organism detection system, total organic carbon (TOC) analysis, enzyme substrate method, and automatic detection system for cryptosporidium and giardia. In addition, the company offers filtration membranes, such as flat and blotting membranes, IVD series, membrane filters and dispensers; and analytical instruments, including filter integrity testing, container closure integrity testers (CCIT), water activity meters, and biodegradation analysis systems. Its products are used in biopharmaceuticals, medical and health care, laboratory animal research, food safety, disease control, water quality monitoring, and environmental protection. The company was formerly known as Hangzhou Tailin Biotechnology Equipment Co., Ltd. and changed its name to Zhejiang Tailin BioEngineering Co.,Ltd in April 2015. Zhejiang Tailin BioEngineering Co.,Ltd was founded in 1993 and is based in Hangzhou, China.
Zhejiang Tailin Bioengineering Co Ltd management
6- Mr. Da Lin YeGM & Chairman · born 1960
- Mr. Xing Yue YeCFO & Secretary of the Board · born 1974
- Mr. Zhi Lin ShenDeputy GM & Director · born 1971
- Mr. Xin Qun XiaDeputy GM & Director · born 1967
- Mr. Xiaolu NiGeneral Manager of Tailin Life Sciences Division & Director · born 1991
- Wen Qin ZhouAccounting Supervisor